Country: Арменија
Језик: Енглески
Извор: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
gestodene, ethinylestradiol
Gedeon Richter PLC
G03AA10
gestodene, ethinylestradiol
0,02mg+ 0,075mg
tablets coated
(21/1x21/) and (63/3x21/) in blister
Prescription
Registered
2018-06-27
PIHCTPYKUI{ff
IIo
ivreArxqH[rcKo&r]f
npilMetleH]rrc
JreKapcrBeHHor0
cpeAcrBS
Toproeoe
r.l
n3B,l
rI
r.le
rp
e
nrrpara
:
Jlu
uguHer 20
(Lind
ynette
2
0)
Mexr,4yrra
pog
soe
fi
erlareliroBall
Hoe
tIa3BaHI{€
(M}III)
I
leorogeH
*
Srnnprns
c'rpa4nor/
Cestodene
+
Ethi
nylestradiol
Oopnh
BbrrrycKa:Ta6lerru,
noKpbrrbre
o6oloqroft
Cocrae
Itaxc4aa
tadlrer:ca
eoAep)Itt,tr:
,[efrcmaynu,qes
ser:qectn$o:
0,075
Mr
rec1'oAeHa
u
0,02
I\/ir
3Tl{H[lIl3QTpaAI4olra
Bctto*tozantefl
b
t
IbIe
&
e
urecn,
Ga:
.fjlpo
rablprrtt:
r{arpu!
IcaJibur,ir
D,(erirr)
ivralur.ir
creapar,
KpeMr"tnl
llrzoncraA
ronlon,{sufr
6egn oAu
sr
[,
noBH.IIo
H
K-3
0,
rpaxuan
tcy
Kypy3
H
stii,
raKto:
LI
tvr
oH
on4
Apar.
06orq.Jrca:
nnulenoE
KpacnTenb
xHrroJrr,rHoBbri.r,
xelrnft
(E
104),
nosugouK-9OF,
rutaua
AnoKcaA
(8171),
MaKporoJr
6000,
rarrx,
r(aJrbqlrx
xap6ouar,
caxapo3a,
Onncanue
Cneuo-NelTbre
KpyrJrbre
ABolKoBbrnyrur.sre
ra6re'rnli,
rroKpblrLle
o6ono'n
Прочитајте комплетан документ
Sunrnrary of Product Chrrracteristics 1., N,A.ME OF TI{E MEDICINAI,I'RODIjCT Lindynette 20 2, QUAI,ITATIVE ANDQUAI\TITATTVBCOMPOS]TION Each table.ts contains: Aclive sabsktncas: 0,0^15 rng of gestodene and 0,02 mg of etlrinylestr.adiol in each goatecl tablst. Excfuients: Sodiurn calciLurt edetate, nragnesiuLn stearate, sitica colloiclal anhyclrous, pgvidone l(-30, naize starch, lactose rronohydrate Filnt-coating,' Quinoline" Yellorv (E 104), povidone K-90F, xitaniurn dioxicle (8171),rnacrogol 6000, talc, calciutn carbon ate, sucrose. 3, PI-IAITNTACEUTICAL FORM Pale yellow, round, biconvex sugar-coetecl tablets, withourt sign o1 the botli sides, 4, CI"INICALPARTICUI,ARS 4.1 Tlrerapeutic indications Oral contraception. The decision to prescribe Lindynette should talie jnto consiileration the jndiviciual woman,s currenr risk factors, partlcr"rlarly those for venoils flrronrboernbolisnr (VTE), and horry the |isk of VTE rvittr Lindynefte conlpares rvith other cornbined hormonal contraceptjves (see sections 4.3 and 4.4). 4,2 Fosology and methocl of adnrinlstr.ation P:'egnancy should be exch"rded before starting Lindynette. Posology The tablets tlust be taken every dai, a1 o6ort the same tine, .in the olclel shorvn on the blister pack. One tablet is to be taken daily for 2l consecutive days, rvhich is follor.ved by a T-clay tablet-fiee interval' Each subsequgnt p^lr"k. is stafted lle da,y after tho tablet-free intsrval. Withdrarval bleecling usually stalts on the 2od or 3"r day after taking tire iast tabJet, and txay uot stop before the next pack is stalted. florv to stirrt Lintlynette No hopronal contracentjve usg_fv,illr j.n thqptecedhe Eo[!h The user shoulcl begin taking.Lindynette on clay I of her natural rrrenslrual cycle (i,e. the 11.st day ot the nrenstlual blecding), Beginning Lindyrette use on days 2-7 of the nrenstiual cycle (e.g. starling on a Sunday) is also allowed; horvevel a non-honnonal back-up rnethocl of bir.th control [o,glcondon:rs, spermicide] is recorr:mencled cluring tlre first ? ctays of Linclyne Прочитајте комплетан документ